757975-87-4

Upstream product

• 757976-48-0 N²-(biphenyl-3-yl)-N-((1S)-1-{[(4-hydroxyphenyl)amino]methyl}propyl)-N²-(biphenyl-3-yl)-L-leucinamide 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 61-90-5 L-leucine 
• 51388-20-6 4-benzyloxyaniline hydrochloride 
• 2113-57-7 3-bromobiphenyl 
• 757975-84-1 N¹-[(1S)-1-({[4-(benzyloxy)phenyl]amino}methyl)propyl]-N²-(biphenyl-3-yl)-L-leucinamide 
• 882296-91-5 (1-{[(4-benzyloxy-phenyl)-(2-nitro-benzenesulfonyl)-amino]-methyl}-propyl)-carbamic acid tert-butyl ester 
• 757976-46-8 tert-butyl [(1S)-1-({[4-(benzyloxy)phenyl]amino}methyl)propyl]carbamate 
• 313067-82-2 N-[4-(benzyloxy)phenyl]-2-nitrobenzenesulfonamide 
• 757976-17-3 N-(biphenyl-3-yl)-L-leucine 

Relevant academic research and scientific papers

4-Aminophenoxyacetic acids as a novel class of reversible cathepsin K inhibitors

We have designed and synthesized a novel series of 3-biphenylamino acid amides as cathepsin K inhibitors based on compound I. In these inhibitors, we have discovered 4-aminophenoxyacetic acids 43 and 47 with good IC50 values, although lipophili

Potent and selective cathepsin K inhibitors

A novel series of cathepsin K inhibitors derived from Novartis compound I is described. Optimization of the P1, P3, and P1′ units led to the identification of 4-aminophenoxyacetic acid 24b with an IC50 value of 4.8 nM, which possessed an excell

Arylamine based cathepsin K inhibitors: Investigating P3 heterocyclic substituents

A modification of novel cathepsin K inhibitors I was carried out. The structural design was aimed at reducing the lipophilic character of compounds I for obtaining better pharmacokinetic profiles. This modification afforded several less lipophilic compoun